No abstract

Systematic literature research limited to studies published from February 2006 to February 2016 was performed with the aim of identifying and analyzing all cost-effectiveness and other economic evaluation studies that investigated the economic and health outcomes of NPs use as screening and management tools for HF. Expert commentary: NP testing either added in the standard of care, or substituting frequently used diagnostic procedures for the diagnosis and management of HF, regardless of the healthcare setting of interest, was proved to be a valid tool for clinical decision-making. Moreover it was associated with improved patient outcomes and important cost-savings mainly attributed to lower admission and readmission rates, shorter hospitalization length and improved health-related quality of life.

perceptions towards generics were investigated, concluding to the chosen independent variables. Results: A positive attitude (odds ratio > 1) on the safety of generics versus originators was identified for older individuals, those with higher income and those with less bill payment difficulties, people who express trust to the medical community, persons with a positive view towards the pharmaceutical industry, those with a positive view for the drugs in general and persons who are willing to be dispensed and prescribed a generic through its active substance. Similarly, a positive attitude (odds ratio > 1) on the efficacy of generics versus originators exists for higher income individuals, those with less bill payment difficulties, persons that have a positive view for the pharmaceutical industry, those with a positive view for drugs in general, and those who concede their doctor and pharmacist to prescribe and dispense a generic. All variables are statistically significant at the .05 level. ConClusions: Consumer preferences as derived from the perception of the population towards generic drugs should be highly considered when creating policies towards improving generic penetration in the market.

Objectives: Specialized home care as financed service was introduced in primary care in Hungary in 1996. The aim of our study was to investigate the number of cases in specialized home care and its distribution between nursing and physiotherapy services. MethOds: The data come from the database of the National Health Insurance Fund Administration, being the only health financing agency in Hungary, and the Central Statistics Office. We analyzed the disitribution of different types of home care services (nursing and physiotherapy services). The period between 2010-2014 was included into the nationwide analysis. Results: The financed number of cases in specialized home care accounted for 93397 in 2010 and 133342 in 2013. The distribution of the number of cases between specialized care and physiotherapy services amounted to 60% and 40% except for the year of 2013 when the distribution varied with 51.68% and 48.32%. Regarding the number of cases, physiotherapy had the highest incidence min. 32.284 (84.7%) in 2010 and 57.509 (89.26%) within physiotherapy services in 2013 opposite to electrotherapy and speech therapy. cOnclusiOns: Within the number of cases in physiotherapy services, more support of physiotherapy is justifiable.

These costs yielded an ICER of-4170 for the SOF+LDV+RBV,-9515 for the SOF+DCV and-2289 for the SOF+RBV. SOF+DCV regimen was the most cost saving option for cirrhotic and non-cirrhotic patients than the other treatment regimens. Deterministic sensitivity analyses remain robust. ConClusions: This study concludes that SOF+DCVregimen is the most cost saving option that yields the most favorable future health economic outcomes compared to the SOF+pegIFN+RBV group across a broad spectrum of patients, including those with cirrhosis.